JMP Securities Reiterates Market Outperform on Terns Pharma, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Terns Pharma (NASDAQ:TERN) and maintained a $17 price target.
June 30, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Terns Pharma's stock rating has been reiterated as Market Outperform by JMP Securities, with a maintained price target of $17.
The reiteration of the Market Outperform rating and maintained price target by JMP Securities indicates a positive outlook for Terns Pharma. This could potentially attract investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100